Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 14/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 14/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 14/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 13/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716466 | 0.90 | REN (0.48) | RENCYP3A4CHRM2CHRM4CHRM1 | |
| SCHEMBL6234280 | 0.87 | ALDH1A1 (0.44) | CHRM2CHRM4CHRM1CHRM3MAPT | |
| SCHEMBL21248553 | 0.82 | CHRM2 (0.65) | CHRM2CHRM4CHRM1CHRM3MAPT | |
| SCHEMBL27192643 | 0.81 | MEN1 (0.43) | RENCYP3A4CHRM2CHRM4CHRM1 | |
| SCHEMBL6713240 | 0.80 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3MAPT | |
| SCHEMBL6720083 | 0.80 | CYP3A4 (0.46) | RENCYP3A4CHRM2CHRM4CHRM1 | |
| SCHEMBL6719484 | 0.79 | REN (0.46) | RENCYP3A4CHRM2CHRM4CHRM1 | |
| SCHEMBL6238530 | 0.79 | NOTUM (0.40) | CHRM2CHRM4CHRM1CHRM3MAPT | |
| SCHEMBL2090062 | 0.78 | MEN1 (0.60) | CHRM2CHRM4CHRM1CHRM3NPC1 | |
| SCHEMBL6232164 | 0.78 | CHRM2 (0.42) | CHRM2CHRM4CHRM1CHRM3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | claimed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | claimed |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | REN, ACE, HPN | REN 1/4885CYP3A4 2949/4885CHRM2 4480/4885 |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | REN 1/4885CYP3A4 1308/4885CHRM2 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.